BACKGROUND: Conditional survival estimates, which take into consideration the changing risk with increasing survival time, provide a dynamic survival probability and more accurate survival information for clinician decision making. The objective of the current study was to evaluate the conditional disease-specific survival (DSS) for patients with gastric cancer who underwent curative surgery in China. METHODS: In total, 7658 patients with gastric cancer from a multi-institutional cohort in China were included in the analyses. Actuarial DSS was estimated using the Kaplan-Meier method. Three-year conditional DSS (CDS 3 ) of patients who had already survived for x years was estimated as CDS 3 5 DSS(x 1 3)/DSS(x). Cox proportional hazards regression analyses were used to identify the factors related to DSS. RESULTS: The 1-year, 3-year, and 5-year actuarial DSS rates were 88.2%, 64.5%, and 54.6%, respectively. By using CDS estimates, the probabilities that patients would remain alive for an additional 3 years given that they had already survived for 1, 3, and 5 years were 66.6%, 80.2%, and 88.3%, respectively. Patients who had unfavorable tumor characteristics diagnosed initially at surgery had the greatest improvement in CDS and the largest survival gap between actuarial DSS and CDS. CONCLUSIONS:
INTRODUCTION
Although global incidence rates of gastric cancer have decreased in recent years, it remains the fifth most common malignancy and the third leading cause of cancer-related death worldwide. 1 In China, gastric cancer is the second leading cause of cancer-related deaths, and approximately 49,8000 individuals died of gastric cancer in 2015. 2 The 5-year overall survival rate for patients with gastric cancer in China ranges from 10% for those with stage IV disease to 90% for those with stage I disase. [3] [4] [5] For those who have malignant tumors, an accurate assessment of prognosis is critical for both patients and oncologists in clinical decision making, determining the surveillance strategy, and predicting the short-term and long-term survival status. Currently, the American Joint Committee on Cancer (AJCC)/International Union against Cancer TNM staging system is the most widely used prognosis assessment tool for gastric cancer. 6, 7 This staging system has been updated many times, and its predictive accuracy has improved over the past several decades. 3, 4, 8, 9 Recently, a new statistical tool for predicting survival, the nomogram, has been used to evaluate prognosis and has achieved greater accuracy compared with the traditional TNM staging system. [10] [11] [12] [13] However, these methods provide survival information over a certain timeframe based on the clinicopathologic features acquired after surgery, and the predicted survival estimates are constant. Actually, because the risk of death changes over time, the survival probability for patients who already have survived for several years may change compared with the probability predicted immediately after surgery. [14] [15] [16] For patients with gastric cancer, most of recurrences or deaths occur in the first 2 years after surgery. 15 Thus, the longterm survival probability of patients who have already survived for 2 years may be changed, and this new probability could provide more significant prognostic information for decision making.
Conditional survival (CS), which considers the changing hazard rate with increased survival time, 14 provides dynamic risk assessment and more accurate survival information for long-term prognosis. CS has been applied in the assessment of prognosis for many tumors. 15, [17] [18] [19] [20] [21] [22] Previous studies in Korea, Japan, and the United States evaluated CS in patients with gastric cancer and also provided valuable prognostic information. 15, 18, 23, 24 However, to our knowledge, no previous study has assessed CS among patients with gastric cancer in China. Therefore, the objective of the current study was to estimate the CS of patients with gastric cancer using a large, multi-institutional cohort from China.
MATERIALS AND METHODS

Patient Source
The study population was collected from a multiinstitutional cohort consisting of patients who underwent surgery between January 2000 and December 2012 from 3 high-volume gastric cancer centers in China (the Department of Gastric and Pancreatic Surgery at Sun Yat-sen University Cancer Center, Guangzhou; the Department of Surgical Oncology at the First Affiliated Hospital of China Medical University, Shenyang; and the Department of Gastric Cancer Surgery at Tianjin Medical University Cancer Hospital, Tianjin). This study was approved by the institutional ethics committee of each participating institution.
Our cohort included patients whose primary sites codes were C16.0 to C16.9 according to the International Classification of Disease for Oncology, third edition, for potential selection. In addition, on the basis of pathologic reports and surgical findings, patients who had a tumor location classified as esophageal cancer according to the seventh edition of the AJCC Cancer Staging Manual were excluded from this cohort. 6 Patients who underwent curative resection and had histologically identified gastric adenocarcinoma were included. Patients were excluded based on the following criteria: 1) they received preoperative neoadjuvant chemotherapy and/or radiotherapy, 2) they were aged <18 or >90 years, 3) they had incomplete clinicopathologic or follow-up information, and 4) they died from surgical complications during the perioperative period (within 30 days). Finally, 7658 patients were selected for further analysis.
For all patients, the following demographic and pathologic characteristics were collected: age, sex, tumor location, tumor size, Lauren type, depth of tumor invasion, the number of examined lymph nodes (LNs), and metastatic LNs, the follow-up period, and survival status. T-classification and LN (N) status were classified according to the seventh edition of the AJCC Cancer Staging Manual. 6 In addition, the receipt of postoperative adjuvant chemotherapy not only depended on tumor stage and the patient's physical condition but also was influenced by the adverse effects of chemotherapy the regimen, the willingness of the patient, and the patient's economic status. In our 3 high-volume cancer centers, approximately one-half of patients received postoperative adjuvant chemotherapy. 4, 8, 25 Conversely, there was a lack of standard postoperative chemotherapy regimens during the period; the treatment strategy varied greatly between the 3 cancer centers, and patients received many different kinds of regimens during the study period. Therefore, we could not precisely evaluate the effects of adjuvant chemotherapy, which may have an impact on the accuracy of our estimates of CS and disease-specific survival (DSS) after adjuvant chemotherapy. On the basis of these considerations, we did not include adjuvant chemotherapy information in our current study.
All patients received standard follow-up, including laboratory and clinical examinations after discharge from the hospital, every 3 months of the first 3 years, 6 months during the fourth and fifth years, and once each year thereafter until the patient died or the time of the last follow-up (June 30, 2015).
Statistical Analyses
Continuous variables for the summary statistics of the study cohort are presented as mean 6 standard deviation (SD) values or as medians with interquartile ranges (IQRs). Categorical variables are described as counts and proportions. DSS is defined as the time from radical surgical resection to death caused by gastric cancer. DSS was calculated using the Kaplan-Meier method, and survival was compared using the log-rank test. A multivariate Cox proportional-hazards regression model was applied to identify the independent prognostic predictors among potential clinicopathologic characteristics. Only those variates with P values < .05 in univariate analyses were included in the multivariate analyses.
CS is estimated as the probability that patients will survive for an additional y years given that they have already survived for x years. The mathematical formula for the estimated CS can be expressed as follows: CS (yjx) 5 S(x 1 y)/S(x), where S(x) represents the actual survival (S) at x years. In the current study, we estimated the 3-year conditional DSS (CDS 3 ) of patients who had already survived for x years using the mathematical formula CDS 3 5 CDS (3jx) 5 DSS(x 1 3)/DSS(x).We also evaluated the CDS 3 stratified by several clinicopathologic characteristics. Changes in CDS 3 rates over time were assessed using linear regression analysis.
The analyses were performed using the R software package (version 3.2.0; R Foundation for Statistical Computing, Vienna, Austria; available at: http://www.r-project.org/, Accessed August 15, 2017) and SPSS (version 21.0; SPSS Inc, Chicago, IL). A 2-tailed P value < .05 was considered statistically significant in all analyses.
RESULTS
Clinicopathologic Characteristics
In total, 7658 patients who underwent radical resection and met our criteria were included in our analysis cohort. The demographics and tumor characteristics of these included patients are presented in Supporting Table 1 (see online supporting information). The median age of our cohort was 59 years (IQR, 50-67 years), and most patients were men (N 5 5403; 70.6%). The median tumor size was 4.5 cm (IQR, 3.0-6.0cm). Almost one-half of tumors were located in the lower one-third of the stomach (N 5 3500; 45.7%). Most of patients were classified with T3 or T4 disease (69.2%; N 5 5298), whereas only a minority of patients had T1 or T2 disease according to the seventh AJCC TNM staging system (30.8%; N 5 2360). For N status, approximately 1 in 3 patients had no LN metastasis (36.7%; n 5 2809) and approximately 70% had sufficient LNs retrieved (>15 LNs; 69.9%; N 5 5355). The mean 6 SD numbers of metastatic and retrieved LNs were 4.94 6 7.53 and 23.16 6 13.09, respectively.
Traditional Actuarial DSS
At the time of the last follow-up, the median follow-up was 37.0 months, and 3248 patients (42.4%) had died. The 1-year, 3-year, and 5-year DSS was 88.2%, 64.5%, and 54.6%, respectively (Fig. 1a) . In univariate analysis, the factors age, tumor size, tumor location, Lauren type, T-classification, N status, and the number of retrieved LNs (>15 vs 15 LNs) were significantly associated with DSS (all P < .05) (Supporting Table 2 ; see online supporting information). In multivariate analysis, after adjusting other competing prognostic factors, factors that were significantly associated with DSS were age, tumor size, tumor location, Lauren type, T-classification, N status, and the number of retrieved LNs (>15 vs 15 LNs; all P < .05).
CDS and Comparison With Actuarial DSS
When we assessed the hazard rate over time, the hazard of death increased immediately after surgery, peaked at 13 months, and subsequently decreased thereafter (Fig. 1b) . The actuarial DSS over the 3 years after surgery and 3-year CS for those who had already survived 1 to 5 years after surgery are presented at Figure 2 . The CDS 3 at 1 year after surgery (the probability of surviving to 4 years after surgery for patients who had already survived for 1 year) was 66.6%, whereas the actuarial DSS at 4 years after surgery was 58.7. Similarly, the CDS 3 at 5 years after surgery (the probability of surviving to 8 years after surgery for patients who had already survived for 5 years) was 88.3% compared with an actuarial DSS at 8 years of 48.2%. The CDS 3 increased over time from 64.5% to 88.3% (P < .05), whereas the actuarial DSS decreased over time from 64.5% at 3 years to 48.2% at 8 years. Table 1 presents the detailed probability of CS for patients who survive up to a certain time point based on how long they have already survived. For example, if a patient was alive at 1 year, 2 years, 3 years, and 4 years after surgery, then their probabilities of remaining alive at 5 years were 61.9%, 73.4%, 84.7%, and 93.0%, respectively.
The effects of clinicopathologic characteristics on actuarial and conditional DSS were assessed by subgroup analyses of patients according to the independent prognostic factors associated with DSS identified in multivariate Cox regression analysis. The actuarial DSS and CDS 3 at different time points are presented in Figures 3 and 4 . The actuarial DSS in each subgroup decreased over time, whereas the CDS 3 increased after surgery. Furthermore, the CDS 3 exceeded the actuarial DSS for all subgroups in each prognostic factor. It is noteworthy that the survival rate gap between actuarial and conditional DSS was more significant among those patients who initially had unfavorable tumor features. In contrast, patients who initially had more favorable tumor features had a less significant survival rate gap. For example, patients with T4a tumors had an actuarial 8-year DSS of 34.6% compared with a CDS 3 at 5 years after surgery of 81.6% (D 5 47%; P < .001), whereas patients with T1 tumors had an actuarial DSS of 92.6% at 8 years after surgery compared with a CDS 3 at 5 years of 96.8% (D 5 4.2%; P 5 .269) (Fig. 3a,b) . D represents the difference between the CDS3 and the actuarial DSS.
In addition, the changes in CS over time were more substantial in patients who initially had unfavorable tumor features compared with those who initially were considered to have a better prognosis. For example, patients without LN metastasis had smaller changes (86.8%-93.7%; D 5 6.9%; P < .001) versus patients with pathologic N3a status (39.2%-74.5%; D 5 35.3%; P < .001) (Fig. 3d) . This pattern also was identified in other subgroups.
DISCUSSION
Although the standard surgical approach and multiple adjuvant therapy patterns suggested for the treatment of gastric cancer lead to improved survival rates, 26-29 the 5-year survival rates for patients with gastric cancer still ranges from 10% to 90% in China for those who have different tumor features. 3, 4, 8 Traditional assessments of prognosis for patients who have malignant tumors usually report estimated survival rates for certain time points (ie, the 5-year survival rate) according to different tumor stages or characteristics identified from pathology after surgery. However, these estimates are constant, and this simple information cannot provide a precise assessment of prognosis for oncologists and patients, especially when the patient remains alive at a certain predicted time point. CS, a novel prognostic index, considers the changes over time in the risk of survival and estimates dynamic survival rates. 14, 16 Thus, CS could provide more accurate and valuable prognostic information. In the current study, for the first time, we estimated the CS of Chinese patients with gastric cancer using a relatively large, multiinstitutional cohort from 3 high-volume cancer centers. Our results indicate that CS increased with survival time elapsed and was longer than traditional survival at each time point. In addition, patients who were initially diagnosed with unfavorable tumor characteristics had a larger 
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Many previous studies have analyzed the factors associated with prognosis among patients with gastric cancer who undergo curative resection. 11, 12, 30 In agreement with those studies, we identified several factors that were associated significantly with DSS, including age, tumor size, tumor location, Lauren type, depth of tumor invasion, LN metastasis, and the number of examined LNs. All of these factors could predict survival and influence the patient's prognosis, whereas the traditional TNM staging system is based only on depth of invasion (T), N status, and distant metastasis (M). This may explain why patients in the same TNM stage have heterogeneous survival. 11, 13 The nomogram, a new method for assessing prognosis, incorporates more clinicopathologic characteristics into the predicted model and has proven to be superior to the traditional TNM staging system. [11] [12] [13] However, these methods only provide the constant survival rates at a certain time point. [10] [11] [12] [13] Moriwaki et al indicated that survival not only is associated with the tumor characteristics identified at surgery but also is influenced by the length of survival. 31 Actually, the hazard rate of survival is not constant after surgery, and the survival probability at each time point is dynamic. In our current study, the hazard rate for patients increased just after surgery, peaked at 13 months, and decreased thereafter. This result was almost consistent with other previous studies. 14, 15 For patients with gastric cancer, most recurrences and deaths occur in the first 2 years after surgery. 15 In our study, 1868 patients (57.5%) died in the first 2 years. Thus, those patients who remain alive after this dangerous period may have a lower risk of death and a greater chance of surviving for a longer time.
CS estimates consider the changing probability of survival over time and thus provide more accuracy and valuable prognostic information on many different tumors. [15] [16] [17] [19] [20] [21] [22] 32 In our current study, the CDS 3 estimates increased after surgery, and the greatest improvement was observed among patients who initially had unfavorable tumor characteristics. This finding was in accordance with previous studies. 15, [17] [18] [19] For example, patients who had N3b disease had a 44.6% improvement (27.3%-71.9%) in 5-year CDS 3 compared with a 6.9% improvement (86.8%-93.7%) among those who had N0 disease (Fig. 3d) . More important, the survival gap between actuarial DSS and CDS also was more significant in these patients. For instance, patients who had N3b disease had an actuarial 5-year DSS of only 15.3% compared with a CDS 3 at 2 years after surgery of 37% (Fig. 3c,d ). This indicates that, if patients remain alive 2 years after surgery, then their probability of survival at 5 years would improve from 15.3% to 37%. This dynamic change in the prognostic assessment could help patients reduce their anxiety about survival and improve their quality of life. This effect is more meaningful for patients who initially are predicted to have a worse prognosis. Thus, CS estimates provide more accuracy and a more hopeful prognosis. In addition, CS also may provide valuable information for deciding on a surveillance strategy. Because the risk of death decreases over time and the probability of surviving for additional time increases, the CS estimates may increase and reach a plateau or threshold value. Our results demonstrated that patients with favorable tumor features reach this plateau earlier, whereas those with unfavorable tumor features reach this plateau later. For example, CDS 3 estimates for patients with T2, T3, and T4a disease reached a threshold of 80% at 2 years, 4 years, and 5 years after surgery, respectively. However, the CDS 3 for patients with T4b disease was still <80% 5 years after surgery. In addition, patients with early stage (T1) gastric cancer achieved excellent CDS 3 estimates initially after surgery, and their status remained extremely high until 5 years after surgery (Fig. 3b) . These results indicate that the standard 5 years of follow-up may be longer for patients who reach a survival threshold earlier and may be insufficient for those who reach a survival threshold later. Thus, dynamic CS estimates may have a significant impact on choosing an individualized surveillance strategy, especially during the process of designing and reporting clinical trials.
Our current study had numerous limitations that should be acknowledged. First, our analysis was based on a retrospective, multi-institutional cohort, and selection bias based on diagnoses, treatments, and follow-up may have occurred. Second, the patients included in our study were collected from 3 cancer centers in different regions, and the generalizability of our results may be good. However, this may cause heterogeneity regarding the socioeconomic status of different regions, specific diagnoses, and/ or treatment protocols, such as the skill of the surgeons and the time of surgery (considering early/late diagnosis and disease stage). These heterogeneous and imbalanced factors may occur in our study population and become confounding factors of DSS and CS estimates. More detailed and precise information will be needed in the future study to control for these confounding factors. Third, we did not include adjuvant chemotherapy information in the current study. However, we should Original Article acknowledge that adjuvant chemotherapy may be a confounder for DSS and CS estimates, and we will consider this possibility in future studies.
In conclusion, this study demonstrates that CDS estimates in Chinese patients with gastric cancer are dynamic and increase with survival time elapsed. Patients who had unfavorable tumor characteristics had the greatest improvement in CDS and the greatest survival gap between actuarial DSS. Therefore, CDS could provide a more valuable and precise long-term prognostic evaluation for patients with gastric cancer. This dynamic method for estimating survival may serve as an important prognostic index to help oncologists and patients make treatment decisions, determine the follow-up strategy, and predict short-term and long-term survival status.
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